US · GSK
GSK plc
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Brentford TW8 9GS
- Website
- gsk.com
Price · as of 2025-12-31
$51.61
Market cap 119.27B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $79.40 | +53.85% |
| Intrinsic Value(DCF) | $30.71 | -40.5% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $36.40 | -29.47% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $22.29 | $51.66 | $11.28 | $0.00 | $16.40 |
| 2012 | $23.47 | $49.57 | $8.05 | $0.00 | $15.00 |
| 2013 | $30.63 | $56.58 | $13.47 | $0.00 | $31.40 |
| 2014 | $26.98 | $40.41 | $0.88 | $0.00 | $0.00 |
| 2015 | $25.22 | $57.03 | $13.29 | $0.00 | $69.80 |
| 2016 | $27.18 | $47.82 | $0.00 | $0.00 | $15.10 |
| 2017 | $25.94 | $47.83 | $1.32 | $0.00 | $16.80 |
| 2018 | $29.35 | $50.90 | $12.14 | $0.00 | $25.30 |
| 2019 | $32.56 | $50.03 | $19.44 | $0.00 | $54.40 |
| 2020 | $28.80 | $35.17 | $8.14 | $0.00 | $0.00 |
| 2021 | $34.65 | $43.81 | $9.61 | $0.00 | $34.70 |
| 2022 | $29.75 | $56.22 | $4.83 | $9.50 | $259.90 |
| 2023 | $39.86 | $52.40 | $14.85 | $0.00 | $37.10 |
| 2024 | $38.51 | $48.20 | $5.97 | $0.00 | $19.30 |
| 2025 | $58.29 | $59.28 | $11.58 | $0.00 | $36.40 |
AI valuation
Our deep-learning model estimates GSK plc's (GSK) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $79.40
- Current price
- $51.61
- AI upside
- +53.85%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$30.71
-40.5% upside
Graham-Dodd
—
— upside
Graham Formula
$36.40
-29.47% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| GSK | GSK plc | $51.61 | 119.27B | +15% | -40% | — | -29% | 15.76 | 5.39 | 2.76 | 8.81 | 13.21 | -11.95 | 72.54% | 21.95% | 17.50% | 37.25% | 20.70% | 9.28% | 1.08 | 10.23 | 0.82 | 0.52 | 1.23 | 11935.00% | 183.00% | 6306.00% | 6.61% | 0.33 | 20.23% | 2.85% | 44.90% | 2.85% | 14.61 | 17.58 | 3.21 | 2.24 |
| BMY | Bristol-Myers Squibb Comp… | $62.37 | 127.01B | +7% | -50% | — | -56% | 18.03 | 6.89 | 2.64 | 11.25 | — | -5.68 | 67.65% | 26.34% | 14.63% | 40.54% | 17.21% | 7.73% | 2.55 | 8.41 | 1.26 | 1.08 | 2.54 | -17823.00% | -22.00% | -787.00% | 10.10% | 0.60 | 23.02% | 3.97% | 71.50% | 7.05% | 12.89 | 12.74 | 3.40 | 2.41 |
| CI | Cigna Corporation | $289.82 | 77.42B | -21% | +327% | -97% | +46% | 12.30 | 1.85 | 0.28 | 8.71 | 14.84 | -2.43 | 9.45% | 3.32% | 2.17% | 15.20% | 11.53% | 4.01% | 0.75 | 6.61 | 0.85 | 0.65 | 2.05 | 8292.00% | 1126.00% | -634.00% | 10.85% | 0.17 | 12.88% | 2.08% | 25.60% | 7.58% | 11.08 | 12.06 | 0.37 | 2.69 |
| CVS | CVS Health Corporation | $79.90 | 101.65B | -34% | -49% | — | -73% | 58.52 | 1.38 | 0.26 | 18.90 | — | -2.89 | 13.77% | 2.58% | 0.44% | 2.35% | 5.50% | 0.69% | 1.24 | 3.33 | 0.84 | 0.57 | 8.63 | -6202.00% | 785.00% | 2341.00% | 7.55% | 0.12 | 5.11% | 3.28% | 192.10% | 3.28% | 17.95 | 23.88 | 0.46 | 2.27 |
| ELV | Elevance Health Inc. | $320.00 | 70.63B | -31% | -45% | -71% | +61% | 11.52 | 1.49 | 0.33 | 9.21 | — | 15.04 | 25.56% | 4.07% | 2.84% | 13.29% | 10.26% | 4.75% | 0.76 | 5.79 | 1.24 | 1.24 | 2.46 | -218.00% | 1262.00% | -3027.00% | 4.87% | 0.21 | 4.76% | 2.34% | 27.00% | 7.36% | 10.97 | 28.03 | 0.45 | 2.82 |
| HCA | HCA Healthcare, Inc. | $529.70 | 118.45B | -26% | -56% | -86% | -18% | 18.12 | -20.40 | 1.63 | 11.03 | 62.49 | -7.53 | 41.50% | 15.83% | 8.97% | -159.14% | 22.59% | 11.28% | -8.33 | 5.32 | 0.83 | 0.73 | 3.15 | 2900.00% | 708.00% | 3641.00% | 6.26% | 0.77 | 18.35% | 0.55% | 10.00% | 8.74% | 14.38 | 22.37 | 2.28 | 2.87 |
| MCK | McKesson Corporation | $987.37 | 121.87B | -46% | +187% | — | -38% | 26.01 | -43.65 | 0.25 | 17.57 | 174.88 | -6.68 | 3.48% | 1.22% | 0.92% | -172.11% | 1514.70% | 4.88% | -3.56 | 17.08 | 0.90 | 0.51 | 0.32 | 1487.00% | 1622.00% | 4409.00% | 5.77% | 0.10 | 2267.25% | 0.38% | 9.90% | 5.08% | 21.10 | 17.65 | 0.26 | 5.91 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| VRTX | Vertex Pharmaceuticals In… | $496.83 | 126.19B | -25% | -45% | -71% | -46% | 31.44 | 6.66 | 10.29 | 24.47 | — | 7.25 | 85.03% | 39.43% | 32.74% | 22.54% | 28.97% | 16.24% | 0.21 | 357.95 | 2.90 | 2.24 | -0.24 | -83654.00% | 957.00% | -50413.00% | 2.57% | 0.94 | 22.83% | 0.00% | 0.00% | 1.62% | 25.53 | 38.06 | 10.07 | 12.10 |
| ZTS | Zoetis Inc. | $131.10 | 57.77B | -7% | -40% | -99% | -53% | 21.39 | 17.17 | 6.04 | 15.82 | 212.77 | -131.77 | 70.49% | 38.00% | 28.23% | 65.99% | 28.56% | 18.00% | 2.85 | 14.80 | 3.03 | 1.75 | 1.76 | 1005.00% | 228.00% | -65.00% | 3.99% | 1.30 | 22.78% | 1.55% | 33.30% | 7.21% | 17.89 | 28.19 | 6.80 | 5.80 |
About GSK plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
- CEO
- Luke Victor Miels
- Employees
- 68.63K
- Beta
- 0.27
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($30.71 ÷ $51.61) − 1 = -40.5% (DCF, example).